Rene Russo - Jan 1, 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Christopher Frankenfield, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Jan 1, 2024
Transactions value $
$0
Form type
4
Date filed
1/3/2024, 04:15 PM
Previous filing
Aug 18, 2023
Next filing
May 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Restricted Stock Units Award $0 +177K $0.00 177K Jan 1, 2024 Common Stock 177K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F2 These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.